- Screening
- Baseline
- In the process of the treatment
- At the end of the treatment
- Follow-up 1
- Follow-up 2
- Follow-up 3
- Management system of participants
- Speciman management system
- Data management system
- ADR/ADE management system
- Madicine management system
- Instruments management system
- SOPs
- Research team
|
group | group B
|
|
recurrent hospitalization due to heart failure caused by volume overload (at least twice in the preceding 12 months) | Yes
|
|
heart function cannot be improved or sustained despite of maximal conservative treatment including large dose of diuretics | Yes
|
|
the extent of heart failure is assessed as stage III or IV based on the New York Heart Association (NYHA) functional classification | Yes
|
|
aged above 18 years | Yes
|
|
ratio of serum urea to creatinine concentrations is less than or equal to 10 | No
|
|
estimated glomerular filtration rate (eGFR) calculated by Modification of Diet in Renal Disease (MDRD) equation is less than 10 mL/min/1.73m2 | No
|
|
patients who suffered from an acute deterioration of heart and/or renal function | No
|
|
triglyceride | 2.73 mmol/L |
|
total cholesterol | 5.11 mmol/L |
|
Atrial fibrillation | Yes
|
|
Chronic glomerulonephritis | No
|
|
Hypertension | No
|
|
Idiopathic cardiomyopathy | No
|
|
Rheumatic heart disease | No
|
|
Ischemic cardiomyopathy | Yes
|
|
Insulin | Yes
|
|
Diabetes | Yes
|
|
Ultrasonic echocardiography, UCG | Abnormal with clinical significance
|
|
Description in detail for abnormal |
|
|
left ventricular ejection fractions | 20 % |
|
NYHA class | III级 |
|
Urine output | 660 ml/day |
|
B-type natriuretic peptide | 3328.00 pg/ml |
|
Systolic blood pressure | 139 mmHg |
|
Diastolic blood pressure | 74 mmHg |
|
Body Mass Index | 22.22 |
|
Weight | 59.10 kg |
- Management of the progress
- General information
- Blood Routine Tests
- Urine and Stool Routine Tests
- Blood Electrolytes Tests
- Coagulation Function Tests
- Serum Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Image Examinations
- Nervous System Examination
- Blood Gas Analysis
- Physical Ability Examination
- Health Relative Quality of Life
|
Residual renal function | 10.49 ml/min |
|
BUN/Cr | 10.40 |
|
eGFR | 11.04 ml/min |
|
Statins | Atorvastatin
|
|
Anticoagulation or antiplatelet agents | Aspirin
|
|
|
|
Name of the drug |
|
|
hemoglobin | 82.40 g/L |
|
serum albumin | 27.30 g/L |
|
QT interval extension | Yes
|
|
Erythropoiesis-stimulating agents(ESAs) | No
|
|
Beta blockers | Yes
|
|
Diuretics | Yes
|
|
RASI(Renin angiotensin system inhibitor) | Yes
|
|
Prognosis | hemodialysis
|
|
Residual renal function | 12.49 ml/min |
|
Duration of Peritoneal Dialysis | 14 months |
|
Ultrasonic echocardiography, UCG | Abnormal with clinical significance
|
|
Description in detail for abnormal |
|
|
left ventricular ejection fractions | 55 % |
|
NYHA class | III级 |
|
Peritoneal ultrafiltation | 1135 ml/day |
|
Urine output | 900 ml/day |
|
B-type natriuretic peptide | 586.00 pg/ml |
- Management for Progress
- Physical examination
- Blood Routine Tests
- Urine and Stool Routine Tests
- Serum Electrolytes Tests
- Liver Function Tests
- HBV Markers Test
- Renel Function Test
- Heat Function Examination
- Image Examinations
- Nervous System Examination
- Blood Gas Analysis
- Physical Sbility Examination
- Health Relative Quality of Life
|
systolic pressure | 128 mmHg |
|
diastolic pressure | 78 mmHg |
|
Weight | 52.60 kg |
|
hemoglobin | 96.90 g/L |
|
serum albumin | 29.30 g/L |
|
Other reasons for rehospitalization | Edema
/Syncope
|
|
Catheter related rehospitalization | Peritonitis
|
|
Tmies of Rehospitalization | 3 |
|
Bacterial species of peritonitis | Escherichia coli
|
|
Times of peritonitis | 1 |
|
Technical survival | No
|
|
Cause of death | |
|
Death | No
|